Farglitazar
Jump to navigation
Jump to search
Clinical data | |
---|---|
Pregnancy category |
|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C34H30N2O5 |
Molar mass | 546.623 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.[1] After reaching phase III for type 2 diabetes, further development was discontinued.[2][3]
References
- ^ McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
- ^ "Farglitazar". Adis Insight. Springer Nature Switzerland AG.
- ^ "Farglitazar". pharmacodia.com.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Articles with changed InChI identifier
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs developed by GSK plc
- PPAR agonists
- Oxazoles
- Abandoned drugs
- All stub articles
- Gastrointestinal system drug stubs